Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P59768

UPID:
GBG2_HUMAN

ALTERNATIVE NAMES:
G gamma-I

ALTERNATIVE UPACC:
P59768; Q5JPE2; Q6P9A9

BACKGROUND:
Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2, or G gamma-I, is integral to the modulation and transduction of signals across cell membranes. It ensures the proper functioning of GTPase activity, the exchange of GDP for GTP, and the interaction between G proteins and effectors. The protein's function is critical for the accurate transmission of cellular signals.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2 offers a promising avenue for the development of novel therapeutic approaches. Its involvement in key signaling pathways makes it a potential target for correcting signal transduction anomalies in various diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.